Information for the public
What has NICE said?
Everolimus (Afinitor), given with a drug called exemestane, is recommended. It is a possible treatment for advanced breast cancer without symptomatic visceral disease in postmenopausal women whose cancer:
is human epidermal growth factor receptor 2 (HER2) negative
is hormone-receptor positive and
has come back or got worse after a non-steroidal aromatase inhibitor drug.
If you have advanced breast cancer without symptomatic visceral disease, and your doctor thinks that everolimus is the right treatment, you should be able to have it on the NHS.
Advanced breast cancer without symptomatic visceral disease is cancer that has spread to surrounding tissues or to other parts of the body, but is not causing symptoms as a result of its spread.
HER2 negative means that there are low levels of a protein called HER2 on the surface of the cancer cells. This protein affects cancer growth.
For some women, the hormones oestrogen or progesterone stimulate breast cancer cells to grow. This type of breast cancer is known as hormone-receptor positive.
Everolimus slows down the growth and spread of cancer cells.
NHS Choices may be a good place to find out more.
These organisations can give you advice and support:
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.